Under agency rules, dialysis clinics receive a6 percent profit on their use of Amgen's Epogen. 根据相关部门的规定,血液透析医疗中心在使用Amgen公司生产的Epogen时可以获得6%的利润。
A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent. 一次联邦审判认定Mircera,一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物,触犯了安进的专利权。